Micronoma’s approach to addressing this unmet need utilizes cell-free microbial DNA (cf-mbDNA) biomarkers and machine learning technology to achieve early detection and classification of cancer from minimally invasive liquid biopsy samples. Human tissues, including tumors, are extensively colonized by taxonomically diverse microbes. Intra-tumoral microbial activity and events of cellular turnover and trafficking contribute to shedding of microbial nucleic acids into the bloodstream where they can be captured and detected by a simple blood draw. This is all based on their patent pending Oncobiota™ platform which reveals the cancer-related microbiome with unparalleled specificity and sensitivity. This new minimally invasive and precise microbiome-driven liquid biopsy™ method can detect cancer in its earliest stages, unlike tests that only focus on the human genome, epigenome, or cancer mutation.